COVID-19 | Pfizer says its vaccine is “100%” effective in adolescents after 4 months

The vaccine against COVID-19 of Pfizer remains “100%” effective in adolescents 12 to 15 years of age more than four months after the application of the second dose, the company reported, according to updated data that it hopes will allow full authorization of the immunizer for this age range.

SIGHT: Italy to inoculate a booster dose five months after receiving the COVID-19 vaccine

The Pfizer-BioNTech vaccine currently has one for adolescents, effective since May in the United States.

The companies released updated information on their clinical trial on Monday based on more than 2,200 minors between the ages of 12 and 15.

SIGHT: There is a high rate of infections in areas where they vote for the extreme right, according to a study

The participants have been evaluated for at least four months after the second injection: 30 cases of COVID-19 were recorded among the adolescents who received the placebo and none in the vaccinated group. That is to say,

The data was collected between November 2020 and September 2021, Pfizer said in its statement.

SIGHT: COVID-19 may reduce pain in cancer patients discovered

What’s more, “No serious safety concerns were observed among individuals with at least six months of follow-up,” added the pharmaceutical giant.

The Pfizer and Moderna messenger RNA vaccines have been associated with an increased risk of myocarditis, an inflammation of the heart muscle, mainly among young men. But those cases remain rare and, according to experts.

“These additional data provide additional confidence in the efficacy and safety profile of our vaccine in adolescents,” Pfizer boss Albert Bourla said, quoted in the statement.

The results should serve as the basis for “In the United States and in the world”, According to the company, they did not provide a timetable.

Pfizer’s vaccine was fully licensed in the United States for those 16 and older in August.

• Italy to inoculate a booster dose five months after receiving the COVID-19 vaccine
• There is a high rate of infections in areas where they vote for the extreme right, according to a study
• COVID-19 may reduce pain in cancer patients discovered
• The long and turbulent history of mandatory vaccination programs
• The EMA evaluates the booster dose of Johnson & Johnson vaccine in people over 18 years of age
• COVID-19 may reduce pain in cancer patients discovered
• “There is always a risk of a new variant”: Europe increases coronavirus sequencing
• Health policies based on science and evidence, by Elmer Huerta
• The scientific race to find people resistant to COVID-19
• How long do immune cells against COVID-19 last after vaccination?
• COVID-19 | Is herd immunity the goal we should pursue with vaccination?
• A fish vendor from Wuhan market is the first known case of COVID-19, study reveals
• COVID-19 | Masks, confinement and hand washing: are there more effective measures than others?
• Immunotherapy with killed bacteria reduces mortality and boosts vaccines against COVID-19
• Pfizer and Moderna vaccines may give false positives for COVID-19
• AstraZeneca Antibody Drug 83% Protects Against COVID-19 for Six Months
• Pfizer and Moderna vaccines may give false positives for COVID-19
• How is the first drug against COVID-19 that China would have ready in December?
• 82% of COVID-19 cases in Peru are detected in unvaccinated people

Follow us on twitter:

!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);

.

George Wilson